TY - JOUR
T1 - Immunoglobulin administration for the treatment of CIDP
T2 - IVIG or SCIG?
AU - Allen, Jeffrey A.
AU - Gelinas, Deborah F.
AU - Freimer, Miriam
AU - Runken, M. Chris
AU - Wolfe, Gil I.
N1 - Publisher Copyright:
© 2019 The Authors
PY - 2020/1/15
Y1 - 2020/1/15
N2 - Chronic inflammatory demyelinating polyneuropathy (CIDP) is an acquired neurological disorder characterized clinically by weakness and impaired sensory function evolving over 2 months or more, loss or significant decrease in deep tendon reflexes, and by electrophysiological evidence of peripheral nerve demyelination. Expeditious diagnosis and treatment of CIDP early in the disease course is critical such that irreversible disability can be avoided. Intravenous immunoglobulin (IVIG) is one first-line and maintenance therapy option for CIDP. The US Food & Drug Administration's (FDA's) approval of subcutaneous immunoglobulin (SCIG) in 2018 provides patients with CIDP more treatment options for maintenance therapy. The different options for administration of IG treatment create the need for information to assist clinicians and patients in choosing the optimal therapeutic approach. Considerations for pharmacokinetics, administration procedures, adverse events, patient variables, and cost will all be discussed in this article.
AB - Chronic inflammatory demyelinating polyneuropathy (CIDP) is an acquired neurological disorder characterized clinically by weakness and impaired sensory function evolving over 2 months or more, loss or significant decrease in deep tendon reflexes, and by electrophysiological evidence of peripheral nerve demyelination. Expeditious diagnosis and treatment of CIDP early in the disease course is critical such that irreversible disability can be avoided. Intravenous immunoglobulin (IVIG) is one first-line and maintenance therapy option for CIDP. The US Food & Drug Administration's (FDA's) approval of subcutaneous immunoglobulin (SCIG) in 2018 provides patients with CIDP more treatment options for maintenance therapy. The different options for administration of IG treatment create the need for information to assist clinicians and patients in choosing the optimal therapeutic approach. Considerations for pharmacokinetics, administration procedures, adverse events, patient variables, and cost will all be discussed in this article.
KW - Chronic inflammatory demyelinating polyneuropathy
KW - Intravenous immunoglobulin
KW - Maintenance therapy
KW - Route of administration comparison
KW - Subcutaneous immunoglobulin
UR - http://www.scopus.com/inward/record.url?scp=85075263178&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85075263178&partnerID=8YFLogxK
U2 - 10.1016/j.jns.2019.116497
DO - 10.1016/j.jns.2019.116497
M3 - Article
C2 - 31765922
AN - SCOPUS:85075263178
SN - 0022-510X
VL - 408
JO - Journal of the Neurological Sciences
JF - Journal of the Neurological Sciences
M1 - 116497
ER -